Business Transactions: Should You Structure As Asset or Stock Purchase?

Asset purchases permit buyer to select specific assets and assumed liabilities, with substantial flexibility to leave behind known and unknown liabilities (tax issues, litigation exposure, environmental contamination, employee claims) with the seller entity. Stock purchases transfer ownership of target entity along with all its liabilities (known and unknown), creating substantial buyer exposure but eliminating need to separately convey individual assets, contracts, and licenses. Tax treatment differs significantly: asset purchases provide step-up in basis benefiting buyer through depreciation deductions, while stock purchases provide carryover basis with limited Section 338(h)(10) election available for S corps and consolidated group subsidiaries. Practical complications often determine structure: contract assignment requirements (many contracts prohibit assignment), license transfer issues (medical, financial, environmental), and employee transition (asset purchase requires rehiring; stock purchase preserves existing employment relationships). Our Asset Purchase Agreement practice handles asset vs stock purchase analysis, optimizes tax treatment for both parties, and structures asset transfer mechanics that preserve key contracts, licenses, and employee relationships.

Statutory mergers under Delaware General Corporation Law § 251 (and parallel state statutes) provide simplified transfer of all assets and liabilities by operation of law, eliminating need for individual asset assignments and contract consents. Forward mergers (target merges into buyer) consolidate target into buyer entity with all assets and liabilities transferring automatically, simple structure but potential contract assignment issues if anti-assignment clauses present. Reverse triangular mergers (buyer subsidiary merges into target, with target surviving as buyer subsidiary) preserve target entity identity, contracts, licenses, and operating relationships while transferring ownership through merger consideration. Tax-free reorganizations under IRC § 368 provide non-recognition treatment for target shareholders receiving buyer stock consideration, with substantial planning required to satisfy continuity of interest, continuity of business enterprise, and business purpose requirements. Our Stock Purchase Agreement (SPA) practice handles merger structure analysis, IRC § 368 tax-free reorganization planning, and parallel anti-assignment clause review across deal structuring.

Legal due diligence reviews target's corporate governance (formation documents, board minutes, stockholder records), material contracts (customer/supplier agreements, leases, IP licenses, employment agreements), litigation history, regulatory compliance, and intellectual property ownership. Financial due diligence examines target's audited financials, quality of earnings analysis, working capital trends, customer concentration, and pro forma financial impact of transaction structure. Tax due diligence reviews target's federal and state tax returns, sales/use tax compliance, employment tax compliance, transfer pricing positions, and uncertain tax positions disclosed on Schedule UTP. Specialized diligence includes environmental (CERCLA exposure for asset purchases), IP (patent prosecution history, freedom-to-operate analysis), cybersecurity (data breach history, GDPR/CCPA compliance), and ESG (climate risk, supply chain ethical sourcing). Our Asset Purchase Transactions practice handles legal due diligence coordination, identifies hidden liabilities affecting deal terms, and develops diligence-driven indemnification provisions matching identified risks.

Seller representations and warranties allocate risk for past events and conditions, covering organization (good standing, authority), financial statements accuracy, absence of undisclosed liabilities, tax compliance, intellectual property ownership, contract status, employee matters, and environmental compliance. Indemnification provisions allocate post-closing exposure through caps (typically 10-20% of purchase price), baskets/deductibles (typically 0.5-1% of purchase price threshold), survival periods (typically 12-24 months for general reps, longer for fundamental reps), and escrow holdback (typically 5-10% of purchase price for 12-24 months). Representations and warranties insurance (RWI) has become standard in middle-market and larger deals, with policy limits of 10-20% of deal value, typical retention of 0.5-1% of deal value, and 3-6 year coverage periods supplementing traditional seller indemnification. Recent RWI market changes include increased claim frequency (40%+ of policies experience claims), tighter underwriting on cyber and ESG matters, and parallel pricing pressure with substantial premium variation. Our escrow agreements practice handles reps and warranties drafting, indemnification cap and basket negotiation, and parallel RWI policy procurement across middle-market and larger transactions.

Hart-Scott-Rodino Act requires premerger notification to FTC and DOJ for transactions exceeding statutory thresholds, with 2025 thresholds: $119.5 million size of transaction, with size of person test for smaller deals. HSR filing fees range $30,000 (smallest) to $2.39 million (largest deals) under 2024 fee schedule, with substantial premium for second-stage filings. HSR review includes 30-day initial waiting period with potential Second Request extending timeline 60+ days for substantive antitrust analysis, particularly for horizontal mergers in concentrated markets. FTC issued substantial HSR rule overhaul (October 2024, effective February 2025) requiring expanded merger filings with substantial new disclosures, though implementation has faced legal challenge. Our Joint Venture and Strategic Alliance practice handles HSR filing preparation, antitrust risk assessment, and parallel Second Request response strategy across complex merger reviews.

Committee on Foreign Investment in the United States (CFIUS) reviews foreign investment in US businesses for national security implications under DPA § 721, with mandatory filings required for certain transactions involving foreign government ownership or critical technology, infrastructure, or data businesses. CFIUS Final Rule on Mandatory Filings (2020, updated 2022) requires filings for foreign investments in TID US businesses (critical technology, critical infrastructure, sensitive personal data) with substantial transaction structuring implications. International transactions also implicate antitrust review in target's home jurisdiction (EU Merger Regulation, UK CMA review, China SAMR review) with parallel timing coordination required. Export control compliance (EAR, ITAR) and sanctions compliance (OFAC) require diligence and post-closing transition planning to avoid violations during integration. Our Asset Disposition practice handles CFIUS filing analysis, coordinates multi-jurisdictional antitrust filings, and develops post-closing compliance frameworks across cross-border transactions.

Material Adverse Change (MAC) clauses permit buyer to terminate transaction or refuse to close when target experiences specified adverse changes, with substantial Delaware Chancery Court jurisprudence shaping interpretation. Akorn, Inc. .. Fresenius Kabi AG (Del. Ch. 2018) was first Delaware Chancery decision finding MAC actually occurred, permitting Fresenius to terminate Akorn acquisition due to severe and durable decline in Akorn's financial performance and regulatory compliance issues. AB Stable VIII LLC v. MAPS Hotels and Resorts One LLC (Del. Ch. November 2020) addressed COVID-related MAC claims in real estate transaction, finding pandemic-related operational changes did not constitute MAC under specific contractual exclusions. Snow Phipps Group, LLC v. KCAKE Acquisition, Inc. (Del. Ch. April 2021) found buyer could not invoke MAC clause when industry-wide impacts excluded from MAC definition. Buyer remedies in post-closing disputes include specific performance (most common), termination, damages, and ordinary breach of contract remedies, with substantial state-by-state variation in specific performance availability. Our breach of contract practice handles MAC clause negotiation, post-closing termination disputes, and parallel specific performance litigation across complex M&A disputes.

Earnout provisions defer portion of purchase price based on target's post-closing performance (revenue, EBITDA, milestone achievement) with substantial disputes when targets miss thresholds or buyer operations affect outcomes. Common earnout disputes include buyer manipulation of operations to suppress earnout payments, calculation methodology disagreements (treatment of corporate overhead, intercompany transactions), and breach of implied covenant of good faith in operating target during earnout period. Implied covenant of good faith and fair dealing under Delaware law (and parallel states) prohibits buyer from acting to deprive seller of earnout reasonably expected, with substantial litigation around buyer integration decisions affecting target performance. Indemnification claim litigation addresses scope of breach (representation false or merely incomplete), damages calculation (diminution in value vs out-of-pocket), basket and cap application, and survival period compliance with substantial procedural complexity. Coordinated indemnification claims defense manages earnout dispute resolution, builds implied covenant claims, and pursues indemnification recovery within survival periods and procedural deadlines.

Asset purchases permit buyer to select specific assets and assumed liabilities, leaving unwanted liabilities (litigation, taxes, environmental issues, employee claims) with seller entity. Stock purchases transfer ownership of target entity along with all its liabilities, both known and unknown. Tax treatment differs: asset purchases provide step-up basis benefiting buyer through depreciation, while stock purchases provide carryover basis. Practical considerations include contract anti-assignment clauses (favor stock purchase), license transferability issues (often favor stock purchase), and employee transition (asset purchase requires rehiring; stock purchase preserves employment).

M&A transactions typically take 3-6 months from signing to closing depending on complexity, regulatory approvals required, and diligence completion. Smaller asset purchases (under $10M) may close in 30-60 days with limited regulatory review, while larger transactions ($100M+) typically take 4-6 months for HSR antitrust review and detailed diligence. Cross-border transactions involving multiple jurisdictions (CFIUS, EU, UK, China antitrust) often extend 6-12 months given parallel filing requirements and coordination challenges.

M&A transaction costs typically range 1-5% of deal value depending on complexity, with smaller deals (under $25M) often paying 3-5% in combined legal, accounting, banking, and other professional fees. Legal fees for typical middle-market deal ($25-250M) range $150,000-$1.5M+ depending on complexity, regulatory review, and dispute scenarios. HSR filing fees range $30,000-$2.39M based on transaction size, plus parallel international filing fees, due diligence expenses, RWI premiums (typically 2-4% of policy limit), and substantial banker advisory fees for larger transactions.